These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 8075377)
1. Specificity of in vitro covalent binding of tienilic acid metabolites to human liver microsomes in relationship to the type of hepatotoxicity: comparison with two directly hepatotoxic drugs. Lecoeur S; Bonierbale E; Challine D; Gautier JC; Valadon P; Dansette PM; Catinot R; Ballet F; Mansuy D; Beaune PH Chem Res Toxicol; 1994; 7(3):434-42. PubMed ID: 8075377 [TBL] [Abstract][Full Text] [Related]
2. Opposite behaviors of reactive metabolites of tienilic acid and its isomer toward liver proteins: use of specific anti-tienilic acid-protein adduct antibodies and the possible relationship with different hepatotoxic effects of the two compounds. Bonierbale E; Valadon P; Pons C; Desfosses B; Dansette PM; Mansuy D Chem Res Toxicol; 1999 Mar; 12(3):286-96. PubMed ID: 10077492 [TBL] [Abstract][Full Text] [Related]
3. Human-liver cytochromes P-450 expressed in yeast as tools for reactive-metabolite formation studies. Oxidative activation of tienilic acid by cytochromes P-450 2C9 and 2C10. Lopez Garcia MP; Dansette PM; Valadon P; Amar C; Beaune PH; Guengerich FP; Mansuy D Eur J Biochem; 1993 Apr; 213(1):223-32. PubMed ID: 8477697 [TBL] [Abstract][Full Text] [Related]
4. Antigenic targets in tienilic acid hepatitis. Both cytochrome P450 2C11 and 2C11-tienilic acid adducts are transported to the plasma membrane of rat hepatocytes and recognized by human sera. Robin MA; Maratrat M; Le Roy M; Le Breton FP; Bonierbale E; Dansette P; Ballet F; Mansuy D; Pessayre D J Clin Invest; 1996 Sep; 98(6):1471-80. PubMed ID: 8823314 [TBL] [Abstract][Full Text] [Related]
5. Oxidation of tienilic acid by human yeast-expressed cytochromes P-450 2C8, 2C9, 2C18 and 2C19. Evidence that this drug is a mechanism-based inhibitor specific for cytochrome P-450 2C9. Jean P; Lopez-Garcia P; Dansette P; Mansuy D; Goldstein JL Eur J Biochem; 1996 Nov; 241(3):797-804. PubMed ID: 8944768 [TBL] [Abstract][Full Text] [Related]
6. Immunotoxicology and expression of human cytochrome P450 in microorganisms. Beaune P; Bourdi M; Belloc C; Gautier JC; Guengerich FP; Valadon P Toxicology; 1993 Oct; 82(1-3):53-60. PubMed ID: 8236281 [TBL] [Abstract][Full Text] [Related]
7. Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Beaune P; Dansette PM; Mansuy D; Kiffel L; Finck M; Amar C; Leroux JP; Homberg JC Proc Natl Acad Sci U S A; 1987 Jan; 84(2):551-5. PubMed ID: 3540968 [TBL] [Abstract][Full Text] [Related]
8. Thiophene derivatives as new mechanism-based inhibitors of cytochromes P-450: inactivation of yeast-expressed human liver cytochrome P-450 2C9 by tienilic acid. López-Garcia MP; Dansette PM; Mansuy D Biochemistry; 1994 Jan; 33(1):166-75. PubMed ID: 8286335 [TBL] [Abstract][Full Text] [Related]
9. Detection of human hepatitis anti-liver kidney microsomes (LKM2) autoantibodies on rat liver sections is predominantly due to reactivity with rat liver P-450 IIC11. Pons C; Dansette PM; Amar C; Jaouen M; Wolf CR; Gregeois J; Homberg JC; Mansuy D J Pharmacol Exp Ther; 1991 Dec; 259(3):1328-34. PubMed ID: 1762080 [TBL] [Abstract][Full Text] [Related]
10. Hydroxylation and formation of electrophilic metabolites of tienilic acid and its isomer by human liver microsomes. Catalysis by a cytochrome P450 IIC different from that responsible for mephenytoin hydroxylation. Dansette PM; Amar C; Valadon P; Pons C; Beaune PH; Mansuy D Biochem Pharmacol; 1991 Feb; 41(4):553-60. PubMed ID: 1997003 [TBL] [Abstract][Full Text] [Related]
11. Molecular structure and hepatotoxicity: compared data about two closely related thiophene compounds. Mansuy D J Hepatol; 1997; 26 Suppl 2():22-5. PubMed ID: 9204406 [TBL] [Abstract][Full Text] [Related]
12. Mechanism-based inactivation of cytochrome P450s 1A2 and 3A4 by dihydralazine in human liver microsomes. Masubuchi Y; Horie T Chem Res Toxicol; 1999 Oct; 12(10):1028-32. PubMed ID: 10525281 [TBL] [Abstract][Full Text] [Related]
13. Comparison of the substrate specificities of human liver cytochrome P450s 2C9 and 2C18: application to the design of a specific substrate of CYP 2C18. Minoletti C; Dijols S; Dansette PM; Mansuy D Biochemistry; 1999 Jun; 38(24):7828-36. PubMed ID: 10387023 [TBL] [Abstract][Full Text] [Related]
14. Tienilic acid-induced autoimmune hepatitis: anti-liver and-kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9. Lecoeur S; André C; Beaune PH Mol Pharmacol; 1996 Aug; 50(2):326-33. PubMed ID: 8700140 [TBL] [Abstract][Full Text] [Related]
16. The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling. Mancy A; Broto P; Dijols S; Dansette PM; Mansuy D Biochemistry; 1995 Aug; 34(33):10365-75. PubMed ID: 7654690 [TBL] [Abstract][Full Text] [Related]
17. Anti-liver microsomes autoantibodies and dihydralazine-induced hepatitis: specificity of autoantibodies and inductive capacity of the drug. Bourdi M; Gautier JC; Mircheva J; Larrey D; Guillouzo A; Andre C; Belloc C; Beaune PH Mol Pharmacol; 1992 Aug; 42(2):280-5. PubMed ID: 1513326 [TBL] [Abstract][Full Text] [Related]
18. Involvement of cytochrome P450-mediated metabolism in tienilic acid hepatotoxicity in rats. Nishiya T; Kato M; Suzuki T; Maru C; Kataoka H; Hattori C; Mori K; Jindo T; Tanaka Y; Manabe S Toxicol Lett; 2008 Dec; 183(1-3):81-9. PubMed ID: 18992796 [TBL] [Abstract][Full Text] [Related]
19. Mechanism-based inactivation of cytochrome P450 2C9 by tienilic acid and (+/-)-suprofen: a comparison of kinetics and probe substrate selection. Hutzler JM; Balogh LM; Zientek M; Kumar V; Tracy TS Drug Metab Dispos; 2009 Jan; 37(1):59-65. PubMed ID: 18838506 [TBL] [Abstract][Full Text] [Related]
20. Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. Obach RS; Kalgutkar AS; Soglia JR; Zhao SX Chem Res Toxicol; 2008 Sep; 21(9):1814-22. PubMed ID: 18690722 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]